Lv1
18 积分 2024-09-23 加入
Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma
22小时前
求助中
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
3天前
已完结
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
3天前
已完结
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
7天前
已完结
Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma
7天前
已完结
Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma
11天前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
24天前
已完结
Flow Cytometry Method Validation Protocols
24天前
已完结
Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D‐CAR T cells
1个月前
已完结
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
1个月前
已完结
皖公网安备34019202002308
